Lucira Health to Announce Third Quarter 2021 Financial Results
Rhea-AI Summary
Lucira Health, a medical technology firm, will release its third quarter 2021 financial results on November 11, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial results and provide corporate updates. Lucira specializes in innovative infectious disease test kits, offering PCR-quality testing through user-friendly, palm-sized kits that provide accurate COVID-19 results in under 30 minutes. The LUCIRA CHECK IT and All-In-One Test Kits feature SMS verification, catering to travel and work testing requirements.
Positive
- Innovative testing platform providing PCR quality results in 30 minutes.
- User-friendly test kits designed for on-the-spot molecular testing.
- SMS verification feature enhances usability for negative test results.
Negative
- None.
News Market Reaction – LHDX
In the trading session that priced this news, LHDX gained 2.28%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
The conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international callers, using conference ID 8458678. A live and archived webcast of the event can be accessed through the following link ir.lucirahealth.com.
About Lucira Health, Inc.
Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira’s testing platform produces PCR quality molecular testing in a single-use, consumer-friendly, palm-size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA™ CHECK IT COVID-19 Test Kit (OTC) and LUCIRA™ COVID-19 All-In-One Test Kit (Rx) provide PCR quality clinically relevant COVID-19 result within 30 minutes from sample collection. Lucira’s CHECK IT (OTC) also provides a SMS verified digital LUCI PASS test result back to a user’s phone for work, travel and other places where negative test verification may be required.
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
347-620-7010
